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 What Are Placebo and Nocebo 
Effects? 
 Placebo and nocebo effects can be described as 
positive or negative treatment effects respec-
tively, after the administration of an inert or 
active treatment, that are not due to the treat-
ment itself [ 1 ]. Both placebo and nocebo effects 
are most commonly observed on self-reported 
outcomes, such as pain, the most frequently 
investigated symptom in the fi eld [ 2 – 4 ]. 
Extensive neurobiological research also indi-
cates that placebo and nocebo effects are char-
acterized by changes in brain processes, 
immunologic or neuroendocrine responses, and 
the autonomic nervous system [ 5 ,  6 ]. 
 The core mechanism of placebo and nocebo 
effects is expectancy [ 1 ,  7 – 9 ]. The expectation 
that a treatment will be effective can predict and 
even cause positive treatment outcomes to occur, 
whereas the converse is true for expectations of 
harmful treatment effects. These expectations can 
be both conscious and automatically regulated 
[ 10 ] and are induced by learning processes. The 
main learning processes that have been found to 
underlie the induction of expectations in placebo 
and nocebo effects are verbal suggestion, condi-
tioning, and social learning. Verbal suggestions 
are instructions regarding the expected or intended 
treatment outcomes that can, for example, be 
given by a clinician during a consult (e.g., “The 
agent that you have just received is known to pow-
erfully reduce itch in some patients”) [ 2 ,  3 ,  11 –
 15 ]. Conditioning refers to the effects of prior 
treatment experiences on subsequent treatment 
outcomes. Research on the role of conditioning in 
placebo and nocebo effects involves the pairing of 
an originally neutral stimulus (e.g., inert pill) with 
an unconditioned stimulus (e.g., reduced pain 
stimulation) that triggers a reduced pain sensa-
tion. After successful pairing, the inert pill alone 
can elicit a pain reduction [ 11 ,  16 – 23 ]. Social, or 
observational, learning in placebo and nocebo 
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effects entails a patient observing that a treatment 
has positive or negative treatment outcomes for 
another person (either somebody present in real 
life or observed on video), causing the patient to 
experience similar treatment outcomes in response 
to an inert treatment [ 24 – 26 ]. In addition to learn-
ing, contextual factors largely infl uence placebo 
and nocebo effects. Most importantly, the quality 
of the doctor-patient relation plays a signifi cant 
role. Research indicates that a warm and empathic 
attitude, as well as reassurance and validation of 
the patient’s concerns can improve treatment out-
comes and can interact with expectation induc-
tions such as verbal suggestions [ 27 – 31 ]. 
Furthermore, treatment characteristics (e.g., pill 
or injection), characteristics of the patient and cli-
nician (e.g., personality characteristics, profes-
sional status), and the health-care setting can also 
infl uence placebo and nocebo effects [ 7 ,  32 ,  33 ]. 
 What Is the Evidence for Placebo 
and Nocebo Effects on Itch? 
 Placebo and nocebo effects on itch have been 
studied predominantly during the last decade, 
both in the clinical setting and in experiments. A 
recent meta-analysis of clinical trials underscores 
the potency of placebos in the treatment of itch 
[ 34 ]. In this meta-analysis, the placebo arms of 
clinical trials for systemic medications in patients 
with atopic dermatitis, psoriasis, and idiopathic 
urticaria were studied. The patients in the placebo 
arm of the clinical trials showed a 24 %-reduction 
in itch symptoms after systemic placebo treat-
ment. Itch symptoms decreased on average by 1.3 
(95 % confi dence interval 1.0–1.6) on a scale from 
0 to 10, which is in terms of effects size a moder-
ate to large effect. Nocebo effects on itch in the 
clinical setting have, for example, been examined 
in studies investigating allergic reactions after 
(placebo) drug administration. Outpatients from 
allergology departments were blindly exposed to 
an oral challenge of placebo medication as part of 
routine medical practice [ 35 ,  36 ]. Patients had 
been selected on basis of previously experienced 
adverse drug reactions, i.e., generalized itch, urti-
caria, or respiratory symptoms, assuming that 
these patients were vulnerable to nocebo effects 
after adverse drug reactions. Results demon-
strated that up to 27 % of the patients displayed 
nocebo responses, such as itch and skin lesions, 
after the placebo drug administration. 
 In experimental studies, patients’ or healthy 
subjects’ expectations regarding itch increase or 
decrease were induced by the main learning pro-
cesses: verbal suggestion, conditioning, and social 
learning. In studies directed to verbal suggestion 
and conditioning, expectations were induced with 
regard to itch evoked by somatosensory stimuli, 
e.g., histamine [ 37 – 42 ]. Generally, results indicate 
that itch can be amplifi ed by inducing nocebo 
expectations, and lowered by inducing placebo 
expectations [ 37 – 42 ]. Verbal suggestion seems to 
be suffi cient to induce itch nocebo effects, while 
for the induction of placebo effects on itch the com-
bination of verbal suggestion and conditioning 
seems to work best. These fi ndings are comparable 
to other areas, such as pain research [ 1 ]. There is 
preliminary evidence that not only self-report of 
itch, but also physiological skin responses may be 
affected by placebo effects, particularly when using 
a conditioning procedure following histamine 
application [ 43 ,  44 ]. For example, in a conditioning 
study by Goebel and colleagues (2008), the 
repeated administration of an antihistaminic along 
with a novel tasting drink, resulted in a placebo 
effect on the skin responses after substituting the 
antihistaminic by similarly looking placebo medi-
cation offered together with the drink [ 44 ]. A phe-
nomenon closely related to placebo and nocebo 
effects, i.e., contagious itch, involves social learn-
ing. Itch’ contagiousness has originally been dem-
onstrated by a study of Niemeier and colleagues 
[ 45 ], showing that people scratched more during a 
lecture about itch, including itch images, than dur-
ing a neutral lecture. Since then, several studies 
have investigated contagious itch, for example by 
displaying videos depicting scratching people or 
by displaying pictures of insects or allergic reac-
tions (e.g., [ 46 – 50 ]). The itch sensation induced by 
 contagious itch is neurobiologically comparable to 
physically induced itch, e.g., by histamine [ 46 ]. 
These experimental studies on expectation induc-
tions and contagious itch support the role of pla-
cebo and nocebo effects in itch. 
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 Studies from placebo and nocebo effects in 
itch as well as contagious itch studies suggest 
that placebo and nocebo effects seem to play an 
even larger role in itch than in other sensations, 
such as pain (e.g., [ 41 ,  50 ]). The fi nding that itch 
is relatively easily induced by talking about itch 
or by displaying visual stimuli might be related to 
its underlying evolutionary function to protect 
against invaders of the skin, e.g., mosquitos. 
Apparently, when observing itch-related signals 
from the environment, the processing of itch is 
given high priority. In an early stage of informa-
tion processing, attentional processes take care of 
fi ltering – mainly on an automatic level – which 
stimuli should be attended to, and thus more 
extensively processed. Due to its susceptibility to 
suggestion in combination with a high prioritiza-
tion in the processing on an automatic level [ 41 , 
 46 – 48 ], the sensation of itch may be particularly 
sensitive to placebo and nocebo effects. 
 How to Control for Placebo 
and Nocebo Effects? 
 In clinical research and practice, physicians are 
interested to know the “real” treatment effects in 
their patients, independently of possible placebo 
and nocebo effects. Also, clinical trials that usu-
ally consist of an intervention and a placebo arm 
without an additional condition with no treatment, 
cannot disentangle the “true” from placebo effects 
on itch. If physicians or researchers want to con-
trol placebo or nocebo effects in their patients or 
studies, additional procedures are required [ 1 ]. 
 Since expectancies play a major role in the 
induction of placebo and nocebo effects, eliminat-
ing expectancies is the most effective way to con-
trol for placebo and nocebo effects. In open- hidden 
paradigms, the effects of openly administering a 
treatment, in full view of a patient by a clinician 
along with suggestions regarding treatment effects, 
is compared to treatment administration outside of 
the patient’s awareness (hidden, e.g., infusion of 
drug regulated via a machine). Studies using this 
design demonstrate that the effects of active treat-
ments such as morphine are signifi cantly reduced 
when a patient is not aware of its administration 
[ 51 – 55 ]. Another possibility might be (after agree-
ment of the patient about this procedure) not to 
disclose the moment at which the treatment is 
administered or expected to work. In clinical trials, 
it is necessary to add other control conditions to 
take the placebo and nocebo effects into account 
[ 1 ,  56 ]. At least, a condition without any treatment 
components should be added as a comparison 
group. When comparing the placebo condition to 
both the treatment and the control condition with-
out treatment, relatively precise estimations of the 
intervention under investigation can be made. In 
addition, the information given in regular treat-
ments and clinical trials strongly infl uences 
patients, such as the information that a patient has 
a 50 % or 100 % chance of receiving an active 
treatment. Ideally, trials consist of both blinded 
and non-blinded conditions (open-label designs) 
that vary in the amount of knowledge patients have 
about the treatment they receive. However, studies 
have hardly controlled for these placebo and 
nocebo effects in the area of itch. 
 How to Minimize or Alter Nocebo 
Effects? 
 Nocebo responses have a tremendous impact on 
clinical practice as they can initiate or worsen 
adverse treatment effects and reduce treatment effi -
cacy. Particularly the doctor- patient communication 
about side effects of treatments appears to be an 
important trigger for nocebo effects in clinical prac-
tice, based on the main learning processes of verbal 
suggestion, conditioning, and social learning. 
 Whereas information regarding side effects or 
other information relevant for patient decision- 
making should in no case be withheld from 
patients, the way in which this is communicated 
is important, since it has the potential to induce 
unhelpful expectations and consequently nocebo 
effects. For example, a study on infl uenza 
 vaccination showed that fewer adverse events 
were reported after infl uenza vaccination by 
patients who got information about the propor-
tion of persons who tolerated the procedure well 
than by those who were informed about the pro-
portion of persons who experienced adverse 
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events [ 57 ]. Studies on itch have still to be con-
ducted to support this effect of positively framed 
information to patients rather than delivering 
detailed lists of specifi c adverse side effects. 
Additional suggestions to reduce nocebo effects 
are to provide percentages of occurrence of side 
effects instead of using a frequency format and to 
emphasize on patients ability to cope with possi-
ble mild side effects [ 58 ,  59 ]. In addition, experi-
mental studies have shown that positive verbal 
information can minimize nocebo effects. For 
example, providing positive information as well 
as explaining how nocebo effects work to the 
patients can possibly reverse or dilute the effects 
of previously provided negative information as 
shown in studies regarding nocebo-like effects in 
wind turbine sound [ 60 ,  61 ]. The only study in 
the area of itch on this topic is a recent experi-
mental study of our research group, which indi-
cated that inducing positive expectations by 
conditioning and verbal suggestion can eliminate 
previously induced nocebo effects on itch [ 62 ], 
delivering further support for the role of posi-
tively framing information after induction of 
nocebo-effects. Finally, in the context of what is 
ethically desirable, procedures such as permitted 
non-information in which a patient agrees that no 
or less information about possible mild or tempo-
rary side effects is provided, can be considered 
for subgroups of highly anxious patients. For 
these groups, hidden-administration procedures 
for treatments with short-term unpleasant conse-
quences might be possible when previously 
agreed upon by the patient [ 63 ]. 
 For specifi c subgroups of patients with 
highly negative and inadequate expectations 
about a treatment (e.g., due to prior experiences 
of strong side effects or treatment failure), 
additional therapeutic psychological interven-
tions, including techniques to reduce distress 
levels and anxiety (e.g., relaxation techniques), 
provided by a health professional can be an 
option. In addition, imagery of desired out-
come, e.g., positive treatment outcomes, can 
induce positive expectations and enhance treat-
ment outcomes [ 64 ,  65 ]. For example, brief 
imagery of reduced pain when immersing ones 
hand in cold water (by using an image of a 
glove) induced expectations of lowered pain 
and reduced actually experienced pain during a 
subsequent cold pressor task, especially when 
combined with a verbal suggestion regarding 
the effectiveness of the imagery exercise [ 66 ]. 
Comparable techniques for itch have still to be 
developed. 
 In addition to these psychological interven-
tions in the area of doctor-patient communica-
tion, there are studies showing possible promising 
pharmacological or neurobiological pathways. 
For example, Benedetti and colleagues found that 
a nonspecifi c cholecystokinin (CCK) antagonist 
or benzodiazepine diazepam could block nocebo 
hyperalgesia [ 67 ,  68 ]. Possibly, similar interven-
tions could be useful to prevent nocebo responses 
in itch. A more recent development in placebo 
research is transcranial magnetic stimulation 
(TMS) of the right dorsolateral prefrontal cortex 
(rDLPFC) aimed at reducing nocebo effects [ 69 , 
 70 ]. However, much more research is warranted 
on the mechanisms, effects and the neurobiologi-
cal and pharmacological pathways, also in the 
fi eld of itch, before it can be used in clinical 
practice. 
 Can We Use Placebo Effects 
Therapeutically? 
 Placebo effects are largely infl uenced by the way 
in which a treatment is administered and pre-
scribed by the physician. Different techniques 
can be used to optimize expectations and thereby 
make optimal use of placebo effects in the treat-
ment of itch in an ethical way. 
 For the doctor-patient communication, it is 
important to inform the patient about intended 
and expected positive outcomes (and other 
aspects) of itch-reducing treatments in a realistic 
and easy to understand manner, without neglect-
ing to mention possible side effects (i.e., harms). 
In addition to the face-to-face communication, 
written information (e.g., educational leafl ets or 
online information about the treatment) or writ-
ten or recorded testimonies of other patients who 
received successful treatment (e.g., leafl ets by 
patient organizations) can be provided. For 
example, Tang and Colagiuri [ 71 ] found evidence 
that an educational leafl et about the effi cacy of 
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analgesics can enhance the placebo analgesic 
effects of a verbal suggestion. 
 From the perspective of long-term condition-
ing processes, it is important to assess previous 
treatment experiences, since past treatment expe-
riences can transfer to subsequent treatments, 
particularly if treatments are alike [ 72 ,  73 ]. 
Sticking to a route of administration that was pre-
viously experienced to be effective might enhance 
current treatment outcomes. Moreover, adminis-
tering treatments in an open manner and empha-
sizing salient sensory aspects of the treatment 
(e.g., visual, tactile, or olfactory) to enhance 
awareness can establish a strong association 
between the treatment and its symptom relieving 
effects, and might thereby possibly enhance 
treatment effects. Also other contextual factors 
can facilitate these conditioning processes, e.g., 
administering treatment at a fi xed time of the day 
in the same room [ 74 ]. 
 Pharmacological treatment options to make 
optimal use of placebo effects are a promising 
new area of research. For example, by use of 
placebo- controlled drug reduction (PCDR) based 
on the principles of conditioning. PCDR provides 
the option of starting treatment with repeated full 
doses to establish associative learning and replac-
ing medication by placebos later on. For exam-
ple, psoriasis patients who received a full 
corticosteroid dose 25–50 % of the time displayed 
reductions in lesion severity that were equal to 
patients who continuously received a full dose 
and greater than patients who continuously 
received a dose that was reduced with 25–50 % 
[ 75 ]. Finally, recent experimental studies suggest 
that pharmacological treatments, such as oxyto-
cin and vasopressin administration, can directly 
infl uence placebo effects [ 76 ,  77 ], however, this 
research is still in its infancy. 
 What Are the Implications 
for Research and Treatment of Itch? 
 Both clinical and experimental research increas-
ingly support the role that placebo and nocebo 
effects play in itch, which appear comparable to 
other areas, such as pain. In view of the relatively 
limited research on placebo and nocebo effects 
on itch up to now, a major challenge remains 
whether experimental laboratory fi ndings on pla-
cebo and nocebo effects on induced itch of short 
duration in healthy subjects can be generalized to 
patients in a clinical setting. The evidence from 
natural settings, such as studies from contagious 
itch, suggests a high relevance for clinical prac-
tice. Research focusing on both psychological 
and neurobiological mechanisms in healthy sub-
jects and patients can further elucidate the spe-
cifi c mechanisms underlying placebo and nocebo 
effects on itch. This knowledge may help improve 
therapeutic interventions by enhancing favorable 
expectations and reducing unfavorable expecta-
tions in patients suffering from chronic itch 
conditions. 
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